Evaluating the impact of Vitamin D deficiency on analgesic use in primary dysmenorrhoea: A correlation study

Objectives: The study aimed to determine the relationship between serum Vitamin D levels and primary dysmenorrhoea severity, as well as the efficacy of Vitamin D3 supplementation in reducing the concurrent use of analgesics in women with primary dysmenorrhoea. Materials and Methods: For 8 weeks, 65 participants with primary dysmenorrhoea and a Vitamin D insufficiency aged 14–40 received Vitamin D3 supplements once a week. The level of serum Vitamin D was measured at baseline and after 8 weeks. In this study, the Working ability, intensity, location, days of pain, dyssmenorrhea (WaLIDD) score for the severity of dysmenorrhoea and the use of analgesic medicine was assessed at baseline, 4 weeks and 8 weeks. Results: Eight weeks after starting the Vitamin D3 supplementation, serum Vitamin D levels increased significantly from 19.13 ± 5.86 ng/mL to 41.65 ± 8.85 ng/mL ( P < 0.001). At 8 weeks, the WaLIDD score, which gauges the severity of dysmenorrhoea, significantly improved (9.92 ± 1.49–6.54 ± 1.54; P < 0.001) after the intervention. Moreover, the amount of analgesic medications required for each menstrual cycle was significantly reduced after 8 weeks (3.86 ±1.56 at 0.85 ±1.46 at 8 weeks; P < 0.001). However, there was no significant correlation seen in relation to serum Vitamin D levels and pain thresholds. Conclusion: In the final analysis, the overall favourable outcomes indicate that Vitamin D therapy may serve as a supportive treatment for primary dysmenorrhoea.